Fibrosis Models
Advanced fibrosis models that replicate key disease processes to accelerate antifibrotic drug development
Fibrosis is a hallmark of numerous chronic diseases, characterized by excessive extracellular matrix deposition and progressive organ dysfunction. Developing effective antifibrotic therapies requires preclinical models that faithfully replicate the cellular and molecular mechanisms driving fibrotic progression.
At NEPHRIX Biosolutions, we have built a strong reputation in renal fibrosis research and expanded our expertise to other major fibrotic diseases. Using state-of-the-art preclinical models and advanced histological analyses, we accurately reproduce key mechanisms of fibrotic progression and assess therapeutic efficacy with strong translational relevance.
Building on this expertise, we offer a comprehensive range of in vivo fibrosis models across the Kidney, Heart, Lung, and Liver. Each model is designed to mirror organ-specific pathways of fibrotic development, enabling reliable evaluation of anti-fibrotic candidates.
We provide a comprehensive portfolio of models tailored to diverse research needs.
Our Kidney fibrosis models ensure high translational value for preclinical drug assessment:
Our Cardiac fibrosis is a hallmark of many cardiovascular diseases, leading to myocardial stiffening, impaired function and heart failure. We developped preclinical cardiac fibrosis models :
- DOcA-Salt + Ux rat model (Reactive fibrosis)
- Isoprenaline-induced MI (Reparative fibrosis)
Pulmonary fibrosis is a progressive scarring of lung tissue resulting from chronic injury or disease, which can ultimately lead to impaired respiratory function and respiratory failure. We offer preclinical pulmonary fibrosis models, including:s :
- Bleomycin (BLM)-induced pulmonary fibrosis
- Chronic pulmonary bacterial infection
Liver fibrosis is a progressive scarring of the liver tissue resulting from chronic injury or disease, which can ultimately lead to cirrhosis and organ failure. We offer rodent preclinical liver fibrosis models, including :
- Carbon tetrachloride (CCl4) induction
| Organ | Model | Fibrosis Type | Key Readouts |
|---|---|---|---|
| Kidney | UUO | α-SMA, collagen deposition, TGF-β1, kidney weight | Obstructive / tubulointerstitial |
| IRI | Ischemic / post-AKI fibrosis | Tubular injury scores, fibrotic markers, renal function | |
| Adenine Diet | CKD-associated fibrosis | fibrosis Creatinine, BUN, histological fibrosis scoring | |
| Heart | DOCA-Salt + Ux | Reactive cardiac fibrosis | Cardiac collagen content, hypertrophy |
| Isoprenaline MI | Reparative cardiac fibrosis | Infarct size, fibrotic area | |
| Lung | Bleomycin (BLM) | IPF-like pulmonary fibrosis | Ashcroft score, lung histology |
| Chronic bacterial infection | Infectious pulmonary fibrosis | Inflammatory & fibrotic markers, lung architecture | |
| Liver | CCl4 induction | Toxic / chronic liver fibrosis | Fibrotic area, ALT/AST, α-SMA expression |
Additional fibrosis services
- Fibroblast migration – scratch assay; wound closure
- Epithelial migration – scratch assay; wound closure
- Fibrosis assays